Product Information
CIMETIDINE 300 MG/5 ML SOLN is a generic product labeled by PAI Holdings LLC, priced at $0.6002 per ML under NDC 00121102508. Its NADAC has been published 63 times since Jul 23, 2025.
FDA first approved this application on Oct 28, 1997. Its Orange Book therapeutic-equivalence code is AA.
Strength
300 mg/5mL
Manufacturer
PAI Holdings LLCNDC
00121102508
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CIMETIDINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA074664FDA Approved
10/28/1997
TE Code
AA
On Market Since
1/9/2025
Pharmacological Classes
Price Statistics
The NADAC for CIMETIDINE 300 MG/5 ML SOLN has been published 63 times since Jul 23, 2025, and over the history we have for it it has risen 5.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6002 per ML |
|---|---|
| All-time high | $0.6016 (Apr 15, 2026) |
| All-time low | $0.5703 (Jul 23, 2025) |
| 52-week high | $0.6016 |
| 52-week low | $0.5707 |
| Median price | $0.5989 |
| Average price | $0.5876 |
| Largest weekly change | +1.8% (Jan 21, 2026) |
| Weeks tracked | 63 |
| Tracking since | Jul 23, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Cimetidine Hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
PAI Holdings LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cimetidine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-2 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CIMETIDINE 300 MG/5 ML SOLN?
The current National Average Drug Acquisition Cost (NADAC) for CIMETIDINE 300 MG/5 ML SOLN, manufactured by PAI Holdings LLC, is $0.6002 per ML (NDC 00121102508), effective Sep 30, 2026.
How has the price of CIMETIDINE 300 MG/5 ML SOLN changed over time?
Over the history we have for it, the NADAC for CIMETIDINE 300 MG/5 ML SOLN has risen 5.2%. It has been tracked across 63 weekly CMS publications since Jul 23, 2025.
What are the highest and lowest recorded NADAC prices for CIMETIDINE 300 MG/5 ML SOLN?
Since Jul 23, 2025, the NADAC for CIMETIDINE 300 MG/5 ML SOLN has ranged from a low of $0.5703 (Jul 23, 2025) to a high of $0.6016 (Apr 15, 2026), with a median of $0.5989 per ML.
Are there cheaper alternatives to CIMETIDINE 300 MG/5 ML SOLN?
No other NADAC-published product currently shares the active ingredient and strength of CIMETIDINE 300 MG/5 ML SOLN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CIMETIDINE 300 MG/5 ML SOLN?
CIMETIDINE 300 MG/5 ML SOLN (NDC 00121102508) is labeled by PAI Holdings LLC, and CMS classifies it as a generic product.